flanders.bio provides you with insights in the vibrant life sciences sector

Facts & Figures

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

News from flanders.bio and its members

argenx announces results of Annual General Meeting 2017

argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST.

Read more
27
Apr
2017

MDxHealth and Exact Sciences Sign Collaboration Agreement

MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a five-year agreement with Exact Sciences Corp. (Nasdaq: EXAS) for collaboration in the growing field of epigenetics and molecular diagnostics.

27
Apr
2017

Biocartis Group NV: Biocartis Q1 2017 Business Update

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2017, selected post period events and an outlook for the remainder of the year.

26
Apr
2017

Aratana Therapeutics Provides Update on ENTYCE®

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced that it recently met with the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE® (capromorelin oral solution).

26
Apr
2017

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Galapagos NV (Euronext & NASDAQ: GLPG) announces a new Phase 2 Proof-of-Concept study investigating filgotinib and another investigational agent in cutaneous lupus erythematosus (CLE). This study is being led by filgotinib collaboration partner Gilead Sciences, Inc.

27
Apr
2017

MDxHealth and Exact Sciences Sign Collaboration Agreement

MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a five-year agreement with Exact Sciences Corp. (Nasdaq: EXAS) for collaboration in the growing field of epigenetics and molecular diagnostics.

27
Apr
2017

Biocartis Group NV: Biocartis Q1 2017 Business Update

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2017, selected post period events and an outlook for the remainder of the year.

26
Apr
2017

Aratana Therapeutics Provides Update on ENTYCE®

Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced that it recently met with the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) regarding the proposed manufacturing transfer of ENTYCE® (capromorelin oral solution).

26
Apr
2017

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Galapagos NV (Euronext & NASDAQ: GLPG) announces a new Phase 2 Proof-of-Concept study investigating filgotinib and another investigational agent in cutaneous lupus erythematosus (CLE). This study is being led by filgotinib collaboration partner Gilead Sciences, Inc.

Z Life Sciences

Z Life Sciences

1

VIB

2

imec

3

Bio Base Europe Pilot Plant

E-letter archive

UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?